Researchers found that significant weight loss while using GLP-1 medications like Ozempic and Mounjaro is linked to lower risks of serious obesity-related health issues, including sleep apnea and kidney disease. The study highlights that those who lost at least 15% of their body weight experienced marked reductions in their risk for these conditions, while individuals who gained weight faced increased risks, particularly for heart failure.

For people looking to age well, these findings underscore the importance of weight management. If you’re considering or currently using these medications, achieving substantial weight loss could lead to better health outcomes. In the study of nearly 90,000 patients, those who lost significant weight saw their risk of osteoarthritis decrease by 37%, chronic kidney disease by 30%, and obstructive sleep apnea by 69%. This suggests that maintaining a healthy weight can have a profound impact on your overall health as you age.

The research analyzed real-world data from patients who started GLP-1 treatments between January 2021 and June 2024. It tracked their weight changes and subsequent health outcomes over an average of 11 months. While the study provides strong evidence linking weight loss to reduced health risks, it also noted that about half of the participants stopped their medication within a year. Therefore, while the results are promising, they reflect early-stage findings that require further exploration in larger, more controlled trials.

If you’re using GLP-1 medications, consider setting realistic weight loss goals and maintaining a healthy lifestyle to maximize the potential benefits. However, always consult with a healthcare provider before making any changes to your treatment plan.

Source: sciencedaily.com